All In Biotech

Drug Trial Radar · NCT05900401

Delayed Tolerance Through Mixed Chimerism

Last checked: Nov 20, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Oct 1, 2023

Primary completion

Dec 2031

Study completion Dec 2032

Sponsor

Lead sponsor
Massachusetts General HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Ossium Health, Inc.; ITB-Med LLC
First posted
Jun 12, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will examine the safety and effectiveness of a bone marrow transplant after kidney transplant (from either a living or deceased donor). An investigational medication and other treatments will be given prior to and after the transplant to help protect the transplanted kidney from being attacked by the body's immune system

Conditions

  • Kidney Failure
  • Kidney Transplant; Complications
  • Chimera

Interventions

  • Bone Marrow TransplantOther

    Months-Years after standard transplant, patients will undergo bone marrow transplant (either from prospective collection of stem cells from their living donor, or from bone marrow collected at the time of deceased donation)

  • Peripheral Blood Stem Cell CollectionProcedure

    PBSC will be collected from the LD via leukapheresis 1-4 weeks before the scheduled HSCT. The donor will first undergo standard GCSF mobilization: GCSF (can be TBO-GCSF) dosed at 10 mcg/kg/d (rounded to nearest pre-filled syringe) administered subcutaneously daily for 5 consecutive days. On the 5th day, the donor will undergo standard large volume leukapheresis. The target yield will be 2-3 x 106 CD34+ cells / kg of actual recipient body weight. A maximum of 3 days of pheresis will be allowed. A minimum of 2 x 106 CD34+ cells / kg of actual recipient body weight will be required to proceed.

  • FludarabineDrug

    Fludarabine 15 mg/m2/day on days -5 to -3 (3 doses)

  • CyclophosphamideDrug

    Cyclophosphamide (CP) 30 mg/kg/day on days -5 and -4

  • RituximabDrug

    Rituximab on study day -6

  • SiplizumabDrug

    Siplizumab (anti-CD2 mAb) on days, -2, -1, 0 and +1.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of transient mixed chimerismTime frame: 3 months
  2. Incidence of renal allograft toleranceTime frame: 2 years after immunosuppression withdrawal

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.